How much does Rucaparib cost per month?

Rucaparib (Rucaparib), formerly known as AG-014699 and PF-01367338, is a potent, oral, small molecule inhibitor of PARP1, PARP2, and PARP3. It is approved in Europe as monotherapy for recurrent ovarian cancer based on results from Study 10 and the ARIEL2 trial, and as maintenance therapy in the United States and Europe based on results from the ARIEL3 trial. Rucaparib is also approved in the United States for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) associated with deleterious BRCA mutations, based on results from the TRITON2 study.

There is evidence that rucapanib can sensitize cancer cells to chemotherapy. Rucaparib also induces vasodilation, which may increase tumor perfusion and enhance the accumulation of cytotoxic drugs in cancer cells. The absolute oral bioavailability of rucaparib is36%. A stable state was achieved after one week of treatment. Rucaparib can be taken with or without food. Exposure-response analyzes demonstrated that efficacy and safety were dose-related and supported a starting dose of rucaparib at 600 mg twice daily.

The original drug Rucapani has not yet been marketed in the country, so it has not entered the medical insurance coverage standards. The European version of rucapani Original drug, specifications300mg*60 tablets per box sold overseas may cost more than 20,000 yuan (the price may fluctuate due to exchange rates). Based on this approximate calculation, patients may need about 50,000 yuan for one month's use, which is relatively expensive. There are also cheap generic rucapani drugs available overseas, and their pharmaceutical ingredients are basically the same as those of the original rucapani drug. For example, in India, the price of BDR pharmaceutical specifications of 300mg*60 tablets per box may be more than 6,000 yuan (the price may fluctuate due to exchange rate effects).